Levitra Dosage

Consumers have also been urged to verify batch numbers before purchasing medicines and to report suspicious products to local health authorities.

Levitra side effects

Updated Fee Structure To improve services, DRAP revised the fees for 132 regulatory processes, aligning them with current needs.5. Support for Biological Product Trials A new draft guidance document provides a clear roadmap for conducting clinical trials of locally manufactured biological products.6. Good Clinical Practice (GCP) Inspections DRAP is ramping up inspections to ensure clinical trials meet international ethical and scientific standards.7. Quality Alerts The authority has issued warnings about contamination risks in certain products, like ethylene glycol, to protect public health.8. Latest DRAP Newsletter The latest quarterly newsletter is packed with updates, including the extension of the e-reporting system and other initiatives to improve healthcare safety.

Achieving treatment optimization with sildenafil citrate (Viagra(R)) in patients with erectile dysfunction

These updates highlight DRAP’s efforts to ensure quality and compliance in Pakistan’s healthcare system. 🚨 RegAlert 067-025 Public Safety Notice The Drug Regulatory Authority of Pakistan (DRAP) has issued a Rapid Alert against an unregistered and substandard product being sold under the name Levitra 20 mg Tablet (Batch No. BXNZ2488), falsely claiming to be manufactured by Bayer Pharma AG, Germany. Testing by the Central Drugs Laboratory confirmed that this batch is falsified and unregistered. Its safety, quality, and efficacy have not been evaluated or approved. In addition, pharmacies, hospitals, and healthcare providers have been instructed to monitor their supply chains closely and report any quality or safety concerns related to the two medicines to DRAP without delay.

#DRAP #HealthAlert #FakeMedicines #PublicWarning #Pakistan #PharmaSafety #DrugRegulation #Efaston #Paracare #CounterfeitDrugs To view or add a comment, sign in ISLAMABAD: The Drug Regulatory Authority of

Related/similar drugs

𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗣𝗮𝘁𝗵𝘄𝗮𝘆𝘀 🔸There are two main types of listed medicines: 🔸AUST L medicines: These are low-risk and do not undergo pre-market efficacy review. 🔸AUST L(A) medicines: Also low-risk, but they require TGA assessment of efficacy evidence and may carry a “TGA assessed” claim. 𝗦𝗽𝗼𝗻𝘀𝗼𝗿 𝗖𝗲𝗿𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 Sponsors must certify that their medicine: 🔸Is eligible for listing under the Act. 🔸Contains only permissible ingredients and meets all ingredient-related requirements. 🔸Complies with advertising, manufacturing, and GMP standards.

Top 5 tips for maintaining regulatory compliance in the pharmaceutical sector

🔸Has written agreements with all nominated manufacturers. 🔸Includes only approved indications and claims, with supporting evidence. 🔸Does not contain prohibited substances or imports. 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗣𝗿𝗼𝗰𝗲𝘀𝘀 Sponsors use the TGA Business Services portal to: 🔸Enter product details. 🔸Receive an AUST L or AUST L(A) number and certificate. Pakistan (DRAP) has declared two widely available medicines as spurious, directing provincial drug inspectors to immediately seize the affected products from markets across the country.

• Levitra 20 mg Bayer is a popular choice for erectile health issues.
• It should not be used in combination with certain medications like alpha-blockers.
• Men with heart conditions should consult a doctor prior to use.
• The pill’s onset can vary between individuals, typically about 30 minutes.
• It is not an aphrodisiac, and sexual arousal is necessary for effectiveness.
• Levitra 20 mg Bayer is not intended for recreational use.
• The medication’s effectiveness can be influenced by age and health status.
• Overdose symptoms may include priapism, a painful erection lasting several hours.
• Pregnant or breastfeeding women should avoid using Levitra.
• Proper hydration can help reduce some side effects.
• Keep out of reach of children and protected from moisture.

#DRAP #HealthAlert #FakeMedicines #PublicWarning #Pakistan #PharmaSafety #DrugRegulation #Efaston #Paracare #CounterfeitDrugs To view or add a comment, sign in 🚨 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐔𝐩𝐝𝐚𝐭𝐞 - 𝐈𝐜𝐞𝐥𝐚𝐧𝐝: 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐨𝐧 𝐒𝐚𝐟𝐞𝐭𝐲 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 (𝐔𝐩𝐝𝐚𝐭𝐞𝐝 𝟎𝟔 𝐎𝐜𝐭𝐨𝐛𝐞𝐫 𝟐𝟎𝟐𝟓) 📅 𝐏𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝: 06

Dosing information

𝗣𝗼𝘀𝘁-𝗟𝗶𝘀𝘁𝗶𝗻𝗴 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗶𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 Once listed, sponsors must: 🔸Maintain pharmacovigilance records and report adverse events. 🔸Comply with any ingredient-specific conditions (e.g., standards for Ginkgo biloba). 🔸Notify the TGA of overseas recalls or safety issues. 𝗠𝗮𝗸𝗶𝗻𝗴 𝗖𝗵𝗮𝗻𝗴𝗲𝘀 Sponsors may request changes to their ARTG entry to: 🔸Correct errors. 🔸Some changes may result in a new product classification, requiring a separate ARTG entry unless grouped under the “Groups Order.” 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 🙏 for 𝘆𝗼𝘂𝗿 time and please 𝗟𝗶𝗸𝗲 👍, 𝗦𝗵𝗮𝗿𝗲, and/or 𝗖𝗼𝗺𝗺𝗲𝗻𝘁 #medicaldevices #invitrodiagnostics #combinationproducts #qualityassurance #regulatoryaffairs #pharmaceuticals To view or add a comment, sign in 📌𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗲𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝘃𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗹𝗶𝘀𝘁𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 This Therapeutic Goods Administration guidance helps sponsors understand how to legally list low-risk medicines (AUST L and AUST L(A)) on the Australian Register of Therapeutic Goods (ARTG).

Patient resources

🔸Some changes may result in a new product classification, requiring a separate ARTG entry unless grouped under the “Groups Order.” 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 🙏 for 𝘆𝗼𝘂𝗿 time and please 𝗟𝗶𝗸𝗲 👍, 𝗦𝗵𝗮𝗿𝗲, and/or 𝗖𝗼𝗺𝗺𝗲𝗻𝘁 #medicaldevices #invitrodiagnostics #combinationproducts #qualityassurance #regulatoryaffairs #pharmaceuticals To view or add a comment, sign in ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has declared two widely available medicines as spurious, directing provincial drug inspectors to immediately seize the affected products from markets across the country. According to a statement issued on Wednesday, the counterfeit medicines identified are Efaston tablets (Dydrogesterone 10mg) and Paracare suspension 60ml (Paracetamol 120mg/5ml). Laboratory analysis revealed that both products lack active pharmaceutical ingredients, rendering them ineffective and unsafe for public use. DRAP warned that such falsified drugs pose a serious threat to public health, potentially leading to treatment failure, worsening of illness, or life-threatening complications particularly for patients relying on them for essential therapies. The authority has advised citizens to stop using these products immediately and to consult healthcare professionals if they experience any adverse effects. October 2025 The Icelandic Medicines Agency (Lyfjastofnun) has published an updated Guidance on Safety Information on its official website, providing greater clarity on the dissemination and review of safety information in the Icelandic market.

Further information

Alpha-Blockers: In those patients who are stable on alpha-blocker therapy, phosphodiesterase type 5 (PDE5) inhibitors should be initiated at the lowest recommended starting dose. Concomitant treatment should be initiated only if the patient is stable on his alpha-blocker therapy. Stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a phosphodiesterase (PDE5) inhibitor including vardenafil. In those patients who are stable on alpha-blocker therapy, LEVITRA should be initiated at a dose of 5 mg (2.5 mg when used concomitantly with certain CYP3A4 inhibitors). A time interval between dosing should be considered when Levitra is prescribed concomitantly with alpha-blocker therapy.

Related treatment guides

2024 DRAP Updates: What You Need to Know This year, the Drug Regulatory Authority of Pakistan (DRAP) has made some important updates to improve the safety and quality of healthcare products in Pakistan. Here’s a quick breakdown of what’s new: 1. Streamlined Product Enlistment DRAP has made it easier for companies to get herbal, homeopathic, and nutraceutical products enlisted by releasing provisional FIFO lists for applications submitted in 2024.2. Stronger Pharmacovigilance The third edition of the National Pharmacovigilance Guidelines has been published, bringing the system in line with WHO recommendations to ensure safer medicines.3. Easier Reporting for Adverse Drug Reactions DRAP extended its E-Reporting System, making it simpler for companies to report safety concerns and help improve drug monitoring.4. 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 ✓ Clear definition of electronic distribution and what constitutes electronic dissemination of safety information (Section: Dissemination of Safety Information) ✓ Clarification that safety information related to pharmaceutical forms not marketed in Iceland will not be assessed by the Icelandic Medicines Agency (Section: 1.6 Review by the Icelandic Medicines Agency and Dissemination of Safety Information) ✓ Aimed at strengthening regulatory transparency and consistency in safety information handling 𝐖𝐡𝐲 𝐈𝐭

• Levitra 20 mg Bayer has a proven track record for efficacy.
• It’s important to inform your doctor of any side effects experienced.
• Lifestyle changes can improve ED alongside medication.
• Risk factors for ED include diabetes, obesity, and smoking.
• Consultation with a healthcare provider ensures safe use.
• Levitra 20 mg Bayer is suitable for many but not all men.
• Don’t share your medication with others to avoid misuse.
• The tablet’s effects can be unpredictable if taken with certain foods.
• Follow-up testing might be needed for underlying medical issues.
• The medication is part of a comprehensive sexual health plan.
• Use discretion and discretion when discussing medication use.

𝐌𝐚𝐭𝐭𝐞𝐫𝐬 This update enhances efficiency and clarity in the regulatory process, ensuring streamlined communication and compliance for Marketing Authorization Holders (MAHs) operating within Iceland.

• Levitra 20 mg Bayer has been approved by health authorities for ED.
• Follow dosing guidelines strictly to reduce risks.
• Side effects tend to resolve within a few hours after dosing.
• People with vision problems should consult a healthcare provider before use.
• Levitra 20 mg Bayer does not increase sexual desire.
• The medication is effective for many men, but not all.
• Levitra’s patent expiration has led to generic options.
• Use of Levitra 20 mg Bayer in women is not approved or recommended.
• Patients should keep a record of their reactions to the medication.
• Managing stress and lifestyle factors can enhance treatment results.
• Always buy Levitra 20 mg Bayer from reputable pharmacies.

It reinforces a transparent and harmonized approach to safety information management.

🌍 At Viginovix, we continuously monitor global pharmacovigilance and regulatory updates to help our partners uphold compliance, safety excellence, and readiness across all regions.

📩 info@viginovix.com & awanishpandey@viginovix.com 🌐 👉 What are your thoughts on how local regulatory clarifications contribute to global pharmacovigilance harmonization?

What is Levitra?

Use of such medicines can result in treatment failure, adverse reactions, or serious health risks. Regulatory Action: DRAP has instructed its field and provincial authorities to seize this product. Pharmacies, distributors, and healthcare institutions are advised to check their inventories immediately and report any presence of this batch to the authorities. For Healthcare Professionals: Stay vigilant for falsified or unregistered medicines. Report any suspected cases or adverse reactions to DRAP’s pharmacovigilance system.

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction

Always purchase medicines from licensed pharmacies and verify their registration details. Seek medical attention if you experience any unusual effects. Ensuring levitra generic quality medicine safety is a shared responsibility. Read the full notice here: 👉 Rapid Alert : #RegAlert #DRAP #Pharmacovigilance #DrugSafety #HealthcarePakistan #PublicHealth #PharmacyProfession #MedicineAlert #PatientSafety #QualityMatters To view or add a comment, sign in 🚨 RegAlert 067-025 Public Safety Notice The Drug Regulatory Authority of Pakistan (DRAP) has issued a Rapid Alert against an unregistered and substandard product being sold under the name Levitra 20 mg Tablet (Batch No. Read the full notice here: 👉 Rapid Alert : #RegAlert #DRAP #Pharmacovigilance #DrugSafety #HealthcarePakistan #PublicHealth #PharmacyProfession #MedicineAlert #PatientSafety #QualityMatters To view or add a comment, sign in 📌𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝘁𝗵𝗲 𝗹𝗲𝗴𝗶𝘀𝗹𝗮𝘁𝗶𝘃𝗲 𝗳𝗿𝗮𝗺𝗲𝘄𝗼𝗿𝗸 𝗳𝗼𝗿 𝗹𝗶𝘀𝘁𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲𝘀 This Therapeutic Goods Administration guidance helps sponsors understand how to legally list low-risk medicines (AUST L and AUST L(A)) on the Australian Register of Therapeutic Goods (ARTG).